GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Xtant Medical Holdings Inc (AMEX:XTNT) » Definitions » Gross Profit

Xtant Medical Holdings (Xtant Medical Holdings) Gross Profit : $62.2 Mil (TTM As of Mar. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Xtant Medical Holdings Gross Profit?

Xtant Medical Holdings's gross profit for the three months ended in Mar. 2024 was $17.3 Mil. Xtant Medical Holdings's gross profit for the trailing twelve months (TTM) ended in Mar. 2024 was $62.2 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Xtant Medical Holdings's gross profit for the three months ended in Mar. 2024 was $17.3 Mil. Xtant Medical Holdings's Revenue for the three months ended in Mar. 2024 was $27.9 Mil. Therefore, Xtant Medical Holdings's Gross Margin % for the quarter that ended in Mar. 2024 was 62.07%.

Xtant Medical Holdings had a gross margin of 62.07% for the quarter that ended in Mar. 2024 => Durable competitive advantage

During the past 13 years, the highest Gross Margin % of Xtant Medical Holdings was 69.21%. The lowest was 55.44%. And the median was 61.93%.

Warning Sign:

Xtant Medical Holdings Inc gross margin has been in long-term decline. The average rate of decline per year is -1.6%.


Xtant Medical Holdings Gross Profit Historical Data

The historical data trend for Xtant Medical Holdings's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xtant Medical Holdings Gross Profit Chart

Xtant Medical Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 42.52 34.39 32.49 32.14 55.47

Xtant Medical Holdings Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.54 12.46 15.33 17.14 17.30

Competitive Comparison of Xtant Medical Holdings's Gross Profit

For the Medical Devices subindustry, Xtant Medical Holdings's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xtant Medical Holdings's Gross Profit Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Xtant Medical Holdings's Gross Profit distribution charts can be found below:

* The bar in red indicates where Xtant Medical Holdings's Gross Profit falls into.



Xtant Medical Holdings Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Xtant Medical Holdings's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )=Revenue - Cost of Goods Sold
=91.303 - 35.836
=55.5

Xtant Medical Holdings's Gross Profit for the quarter that ended in Mar. 2024 is calculated as

Gross Profit (Q: Mar. 2024 )=Revenue - Cost of Goods Sold
=27.873 - 10.571
=17.3

Gross Profit for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $62.2 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Xtant Medical Holdings's Gross Margin % for the quarter that ended in Mar. 2024 is calculated as

Gross Margin % (Q: Mar. 2024 )=Gross Profit (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=17.3 / 27.873
=62.07 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Xtant Medical Holdings  (AMEX:XTNT) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Xtant Medical Holdings had a gross margin of 62.07% for the quarter that ended in Mar. 2024 => Durable competitive advantage


Xtant Medical Holdings Gross Profit Related Terms

Thank you for viewing the detailed overview of Xtant Medical Holdings's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Xtant Medical Holdings (Xtant Medical Holdings) Business Description

Traded in Other Exchanges
Address
664 Cruiser Lane, Belgrade, MT, USA, 59714
Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect DBM putty, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the US.
Executives
Kevin D Brandt officer: VP & Chief Commercial Officer 11621 RESEARCH CIRCLE, ALACHUA FL 32615
Lori D Mitchell-keller director 664 CRUISER LANE, BELGRADE MT 59714
Jonn R. Beeson director 664 CRUISER LANE, BELGRADE MT 59714
Scott C Neils officer: Interim CFO 664 CRUISER LANE, BELGRADE MT 59714
Mark A. Schallenberger officer: Chief Operations Officer 664 CRUISER LANE, BELGRADE MT 59714
Sean E Browne officer: President and CEO 664 CRUISER LANE, BELGRADE MT 59714
Stavros G. Vizirgianakis director 1/16-18 TENNYSON ST., WILLIAMSTOWN NORTH, VICTORIA CA 3016
Orbimed Rof Ii Llc director, 10 percent owner 601 LEXINGTON AVE., 54TH FLOOR, NEW YORK NY 10022
Greg Jensen officer: VP, Finance and Interim CFO 664 CRUISER LANE, BELGRADE MT 59714
Ronald G. Berlin officer: VP & Chief Operations Officer 664 CRUISER LANE, BELGRADE MT 59714
Kathie J. Lenzen officer: SVP Fiance & Admin. & CFO 664 CRUISER LANE, BELGRADE MT 59714
Orbimed Advisors Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Matthew Rizzo director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Michael Eggenberg director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Robert Mcnamara director C/O LDR HOLDING CORPORATION, 13785 RESEARCH BOULEVARD, SUITE 200, AUSTIN TX 78750

Xtant Medical Holdings (Xtant Medical Holdings) Headlines

From GuruFocus